Provexis PXS.L · GBp

Its shares trade on LSE under the ticker PXS.L. It has been listed since 24 June 2005. In the fiscal year to 31 March 2026, it reported revenue of £1.3m and a net loss of £502,760. At that date it held total assets of £1.3m and shareholders' equity of £1.1m.

Provexis Plc engages in the development and commercialization of Fruitflow, an anti-thrombotic technology. The company is headquartered in Reading, Berkshire. The company went IPO on 2005-06-24. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The firm also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The firm's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. C. Dawson BuckNon-Executive Chairman of the Board£27,600
• Mr. Ian FordChief Executive Officer, Executive Director, Secretary, since 2007£168,749
• Dr. Niamh O'KennedyChief Scientific Officer, Executive Director£94,109

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.